Kempen & Co acted as Lead Co-Manager in Y-mAbs Therapeutics’ USD 115m US Public Offering on the Nasdaq Global Select Market
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: